Jing Han1,2, Yawei Li3, Hong Zhang1, Jinbo Guo1, Xing Wang1, Yaxing Kang1, Yuxin Luo1, Mengyao Wu1, Xiaolan Zhang1. 1. Department of Gastroenterology, The East Branch of The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology Shijiazhuang, China. 2. Department of Physical Examination Center, The Second Hospital of Hebei Medical University Hebei, Shijiazhuang, China. 3. Department of Cardiology, The Third Hospital of Shijiazhuang Shijiazhuang, Hebei, China.
Abstract
BACKGROUND: Increasing evidence suggests that abnormal levels of microRNAs (miRNAs) are associated with ulcerative colitis (UC). It has been demonstrated that microRNA (miR)-142-5p was upregulated in UC patients. However, it remains unclear what the role of miR-142-5p is in UC. METHODS: Samples from patients with active UC and healthy controls were performed with miRNA microarray to identify miRNAs involved in the pathogenesis of UC. The results of quantitative RT-PCR verified that miR-142-5p was upregulated in UC patients. Meanwhile, the decreased expression of suppressor of cytokine signaling 1 (SOCS1) was also detected at mRNA and protein levels. The regulatory effect of miR-142-5p on SOCS1 was evaluated by luciferase reporter assay. Levels of IL-6 or IL-8 were detected by quantitative RT-PCR or enzyme-linked immunosorbent assay in HT-29 cells to evaluate the roles of SOCS1 or miR-142-5p in the progression of UC. RESULTS: The expression level of miR-142-5p was significantly upregulated and inversely correlated with SOCS1. Luciferase experiments showed that miR-142-5p interfered with the expression of SOCS1 by directly targeting its 3'-UTR. Furthermore, the level of miR-142-5p plays an important role in the secretion of IL-6 and IL-8. Moreover, lost function of SOCS1 reversed the miR-142-5p inhibitory effect. CONCLUSIONS: These results indicate that miR-142-5p improved the intestinal inflammation of active-UC patients by downregulating SOCS1 expression and increasing the cytokines IL-6 and IL-8 secretion. IJCEP
BACKGROUND: Increasing evidence suggests that abnormal levels of microRNAs (miRNAs) are associated with ulcerative colitis (UC). It has been demonstrated that microRNA (miR)-142-5p was upregulated in UCpatients. However, it remains unclear what the role of miR-142-5p is in UC. METHODS: Samples from patients with active UC and healthy controls were performed with miRNA microarray to identify miRNAs involved in the pathogenesis of UC. The results of quantitative RT-PCR verified that miR-142-5p was upregulated in UCpatients. Meanwhile, the decreased expression of suppressor of cytokine signaling 1 (SOCS1) was also detected at mRNA and protein levels. The regulatory effect of miR-142-5p on SOCS1 was evaluated by luciferase reporter assay. Levels of IL-6 or IL-8 were detected by quantitative RT-PCR or enzyme-linked immunosorbent assay in HT-29 cells to evaluate the roles of SOCS1 or miR-142-5p in the progression of UC. RESULTS: The expression level of miR-142-5p was significantly upregulated and inversely correlated with SOCS1. Luciferase experiments showed that miR-142-5p interfered with the expression of SOCS1 by directly targeting its 3'-UTR. Furthermore, the level of miR-142-5p plays an important role in the secretion of IL-6 and IL-8. Moreover, lost function of SOCS1 reversed the miR-142-5p inhibitory effect. CONCLUSIONS: These results indicate that miR-142-5p improved the intestinal inflammation of active-UCpatients by downregulating SOCS1 expression and increasing the cytokines IL-6 and IL-8 secretion. IJCEP
Authors: Mehmet Coskun; Jacob Tveiten Bjerrum; Jakob Benedict Seidelin; Ole Haagen Nielsen Journal: World J Gastroenterol Date: 2012-09-14 Impact factor: 5.742
Authors: Claire S Whyte; Eileen T Bishop; Dominik Rückerl; Silvia Gaspar-Pereira; Robert N Barker; Judith E Allen; Andrew J Rees; Heather M Wilson Journal: J Leukoc Biol Date: 2011-05-31 Impact factor: 4.962
Authors: Luke B Roberts; Geraldine M Jowett; Emily Read; Tomas Zabinski; Rita Berkachy; Murray E Selkirk; Ian Jackson; Umar Niazi; Nelomi Anandagoda; Masatake Araki; Kimi Araki; Jagath Kasturiarachchi; Chela James; Tariq Enver; Rachael Nimmo; Rita Reis; Jane K Howard; Joana F Neves; Graham M Lord Journal: J Immunol Date: 2021-05-21 Impact factor: 5.422